Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"Gilead Sciences Pty Ltd, Clinician",Sacituzumab govitecan,"Breast Cancer,  Triple-Negative,Locally Advanced or Metastatic",Sacituzumab govitecan (trodelvy),Options for investment,Hospital,Oncology Agents and Immunosuppressants
